CRISPRとCas遺伝子市場：コンポーネント、用途、エンドユーザー別-2025年～2030年の世界予測

CRISPRとCas遺伝子市場は、2023年に38億1,000万米ドルと評価され、2024年には50億4,000万米ドルに達すると予測され、CAGR 32.40％で成長し、2030年には272億1,000万米ドルになると予測されています。

CRISPRとCas遺伝子市場は、ゲノム編集技術を中心に展開され、生物のDNAに正確で的を絞った改変を提供し、バイオテクノロジー、農業、医学研究に変革をもたらしつつあります。この市場は、改良された作物品種、遺伝性疾患の高度な治療ソリューション、合理化された遺伝子編集法に対する需要の高まりによって大きく牽引されています。応用分野では、CRISPR技術は、病気の治療を目的とした医療用遺伝子治療から、作物の回復力と収量を向上させる農業用アプリケーションまで広がっています。最終用途分野は医薬品、医療、農業、バイオテクノロジー企業など幅広いです。主な成長要因としては、精度と効率を高める技術の進歩、ゲノミクスにおける資金調達と官民パートナーシップの増加、治療開発におけるCRISPRソリューションの受け入れ拡大などが挙げられます。CRISPRに基づく診断、農業分野の進歩、個別化医療や合成生物学への応用の可能性から大きなビジネスチャンスが生まれ、研究開発への投資やイノベーションを促進するための戦略的協力関係の形成が推奨されます。

しかし課題としては、遺伝子編集に関する倫理的懸念、複雑な規制の枠組み、意図しない遺伝子変異につながるオフターゲット効果の可能性などがあります。さらに、知的財産権に関する紛争が市場力学を制限する可能性もあります。データ共有の透明性、CRISPR-Casシステムの忠実性の向上、強固な倫理的ガイドラインの開発を通じて、これらの制限に対処することが極めて重要です。技術革新の道筋として有望なのは、特異性と安全性を向上させた次世代CRISPRシステムの開発、バイオ燃料への応用、複雑な形質操作のための新規遺伝子編集ツールなどです。市場の進化を考えると、規制の変化を追跡し、政策対話に参加し、倫理的諮問グループに関与するという積極的なアプローチが、企業を有利に位置づけることができます。CRISPRとCas遺伝子市場は、急速な技術開拓と分野横断的応用の高い可能性を特徴とし、大幅な成長の態勢を整えているが、その可能性を十分に発揮するためには、規制上および倫理上の数々の課題を乗り越える必要があります。

市場力学：急速に進化するCRISPRとCas遺伝子市場の主要市場インサイトを公開

CRISPRとCas遺伝子市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • サンプル組織スクリーニングのためのCRISPRベースの診断アッセイの開発
  • 遺伝性疾患の高い有病率
  • 創薬、生物医学研究、非トランスジェニック出血におけるアプリケーションの増加
• 市場抑制要因
  • CRISPR技術のオフターゲット効果
• 市場機会
  • 抗CRISPRタンパク質の進化
  • CRISPR-Cas遺伝子の新規応用のための研究開発
• 市場の課題
  • 特許状況と紛争

ポーターの5つの力：CRISPRとCas遺伝子市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：CRISPRとCas遺伝子市場における外部からの影響の把握

外部マクロ環境要因は、CRISPRとCas遺伝子市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析CRISPRとCas遺伝子市場における競合情勢の把握

CRISPRとCas遺伝子市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスCRISPRとCas遺伝子市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、CRISPRとCas遺伝子市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨CRISPRとCas遺伝子市場における成功への道筋を描く

CRISPRとCas遺伝子市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • サンプル組織スクリーニングのためのCRISPRベースの診断アッセイの開発
    • 遺伝性疾患の有病率が高い
    • 創薬、生物医学調査、非遺伝子組み換え出血における応用の増加
  • 抑制要因
    • CRISPR技術のオフターゲット効果
  • 機会
    • 抗CRISPRタンパク質の進化
    • CRISPR-Cas遺伝子の新たな応用に向けた研究開発
  • 課題
    • 特許情勢と紛争
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 CRISPRとCas遺伝子市場：コンポーネント別

• 製品
  • 抗体
  • デザインツール
  • キットと酵素
    • DNAフリーCas
    • ベクターベースのCAS
  • 図書館
• サービス
  • 細胞株エンジニアリング
  • DNA合成
  • gRNA設計
  • 微生物の遺伝子編集

第7章 CRISPRとCas遺伝子市場：用途別

• 農業
• バイオメディカル
  • 疾患モデル研究
  • エピジェネティクス
  • 機能ゲノミクス
  • ゲノム工学

第8章 CRISPRとCas遺伝子市場：エンドユーザー別

• 学術機関および政府研究機関
• バイオテクノロジーおよび製薬会社
• 契約研究機関

第9章 南北アメリカのCRISPRとCas遺伝子市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋のCRISPRとCas遺伝子市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのCRISPRとCas遺伝子市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AstraZeneca plc
• Beam Therapeutics Inc.
• Beckman Coulter, Inc.
• Calyxt, Inc.
• Caribou Biosciences, Inc.
• CRISPR Therapeutics AG
• Danaher Corporation
• Editas Medicine, Inc.
• Hera Biolabs
• Horizon Discovery Group Plc
• Inscripta, Inc.
• Integrated Dna Technologies, Inc.
• Intellia Therapeutics, Inc.
• Lonza Group
• Mammoth Biosciences

LIST OF FIGURES

• FIGURE 1. CRISPR & CAS GENES MARKET RESEARCH PROCESS
• FIGURE 2. CRISPR & CAS GENES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CRISPR & CAS GENES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CRISPR & CAS GENES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CRISPR & CAS GENES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CRISPR & CAS GENES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CRISPR & CAS GENES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CRISPR & CAS GENES MARKET DYNAMICS
• TABLE 7. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DESIGN TOOL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DNA-FREE CAS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VECTOR-BASED CAS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIBRARIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY SERVICE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DNA SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GRNA DESIGN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY MICROBIAL GENE EDITING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY AGRICULTURAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DISEASE MODEL STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EPIGENETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY FUNCTIONAL GENOMICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENOME ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ACADEMICS & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. CANADA CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 58. CANADA CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. CANADA CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 60. CANADA CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 61. CANADA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. CANADA CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 63. CANADA CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 87. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 88. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. CHINA CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 95. CHINA CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. CHINA CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 97. CHINA CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 98. CHINA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. CHINA CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 100. CHINA CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. INDIA CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 102. INDIA CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 103. INDIA CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 104. INDIA CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 105. INDIA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. INDIA CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 107. INDIA CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. INDONESIA CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 109. INDONESIA CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. INDONESIA CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 114. INDONESIA CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. JAPAN CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 116. JAPAN CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. JAPAN CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 121. JAPAN CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. MALAYSIA CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 123. MALAYSIA CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. MALAYSIA CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 128. MALAYSIA CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. PHILIPPINES CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 130. PHILIPPINES CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 133. PHILIPPINES CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. PHILIPPINES CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 135. PHILIPPINES CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. SINGAPORE CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 137. SINGAPORE CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 139. SINGAPORE CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 140. SINGAPORE CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. SINGAPORE CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 142. SINGAPORE CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 144. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 146. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 149. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. TAIWAN CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 151. TAIWAN CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 152. TAIWAN CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 153. TAIWAN CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 154. TAIWAN CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. TAIWAN CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 156. TAIWAN CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. THAILAND CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 158. THAILAND CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 159. THAILAND CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 160. THAILAND CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 161. THAILAND CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. THAILAND CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 163. THAILAND CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. VIETNAM CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 165. VIETNAM CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 166. VIETNAM CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 167. VIETNAM CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 168. VIETNAM CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. VIETNAM CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 170. VIETNAM CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 172. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 179. DENMARK CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 180. DENMARK CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 181. DENMARK CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 182. DENMARK CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 183. DENMARK CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 184. DENMARK CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 185. DENMARK CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. EGYPT CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 187. EGYPT CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 188. EGYPT CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 189. EGYPT CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 190. EGYPT CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 191. EGYPT CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 192. EGYPT CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 193. FINLAND CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 194. FINLAND CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 195. FINLAND CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 196. FINLAND CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 197. FINLAND CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 198. FINLAND CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 199. FINLAND CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 200. FRANCE CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 201. FRANCE CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 202. FRANCE CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 203. FRANCE CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 204. FRANCE CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 205. FRANCE CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 206. FRANCE CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 207. GERMANY CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 208. GERMANY CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 209. GERMANY CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 210. GERMANY CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 211. GERMANY CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. GERMANY CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 213. GERMANY CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 214. ISRAEL CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 215. ISRAEL CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 216. ISRAEL CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 217. ISRAEL CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 218. ISRAEL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 219. ISRAEL CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 220. ISRAEL CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 221. ITALY CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 222. ITALY CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 223. ITALY CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 224. ITALY CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 225. ITALY CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 226. ITALY CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 227. ITALY CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 228. NETHERLANDS CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 229. NETHERLANDS CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 230. NETHERLANDS CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 231. NETHERLANDS CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 232. NETHERLANDS CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 233. NETHERLANDS CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 234. NETHERLANDS CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 235. NIGERIA CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 236. NIGERIA CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 237. NIGERIA CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 238. NIGERIA CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 239. NIGERIA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 240. NIGERIA CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 241. NIGERIA CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 242. NORWAY CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 243. NORWAY CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 244. NORWAY CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 245. NORWAY CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 246. NORWAY CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 247. NORWAY CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 248. NORWAY CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 249. POLAND CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 250. POLAND CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 251. POLAND CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 252. POLAND CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 253. POLAND CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 254. POLAND CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 255. POLAND CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 256. QATAR CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 257. QATAR CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 258. QATAR CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 259. QATAR CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 260. QATAR CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 261. QATAR CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 262. QATAR CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 263. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 264. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 265. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 266. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 267. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 268. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 269. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 270. SAUDI ARABIA CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 271. SAUDI ARABIA CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 272. SAUDI ARABIA CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 273. SAUDI ARABIA CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 274. SAUDI ARABIA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 275. SAUDI ARABIA CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 276. SAUDI ARABIA CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 277. SOUTH AFRICA CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 278. SOUTH AFRICA CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 279. SOUTH AFRICA CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 280. SOUTH AFRICA CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 281. SOUTH AFRICA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 282. SOUTH AFRICA CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 283. SOUTH AFRICA CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 284. SPAIN CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 285. SPAIN CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 286. SPAIN CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 287. SPAIN CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 288. SPAIN CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 289. SPAIN CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 290. SPAIN CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 291. SWEDEN CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 292. SWEDEN CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 293. SWEDEN CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 294. SWEDEN CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 295. SWEDEN CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 296. SWEDEN CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 297. SWEDEN CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 298. SWITZERLAND CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 299. SWITZERLAND CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 300. SWITZERLAND CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 301. SWITZERLAND CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 302. SWITZERLAND CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 303. SWITZERLAND CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 304. SWITZERLAND CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 305. TURKEY CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 306. TURKEY CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 307. TURKEY CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 308. TURKEY CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 309. TURKEY CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 310. TURKEY CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 311. TURKEY CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 312. UNITED ARAB EMIRATES CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 313. UNITED ARAB EMIRATES CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 314. UNITED ARAB EMIRATES CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 315. UNITED ARAB EMIRATES CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 316. UNITED ARAB EMIRATES CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 317. UNITED ARAB EMIRATES CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 318. UNITED ARAB EMIRATES CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 319. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 320. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 321. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY KITS & ENZYMES, 2018-2030 (USD MILLION)
• TABLE 322. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 323. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 324. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY BIOMEDICAL, 2018-2030 (USD MILLION)
• TABLE 325. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 326. CRISPR & CAS GENES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 327. CRISPR & CAS GENES MARKET, FPNV POSITIONING MATRIX, 2023

The CRISPR & Cas Genes Market was valued at USD 3.81 billion in 2023, expected to reach USD 5.04 billion in 2024, and is projected to grow at a CAGR of 32.40%, to USD 27.21 billion by 2030.

The CRISPR & Cas Genes market revolves around genome-editing technology, providing precise and targeted modifications in the DNA of living organisms, which is transforming biotechnology, agriculture, and medical research. This market is significantly driven by the rising demand for improved crop varieties, advanced therapeutic solutions for genetic disorders, and streamlined gene-editing methods. In application, CRISPR technology spans from medical gene therapy aimed at treating diseases to agricultural applications that enhance crop resilience and yield. End-use sectors show a broad range, including pharmaceuticals, medicine, agriculture, and biotechnology companies. Key growth factors include technological advancements enhancing precision and efficiency, increased funding and public-private partnerships in genomics, and a growing acceptance of CRISPR solutions in therapeutic developments. Significant opportunities arise from CRISPR-based diagnostics, agriculture sector advancements, and potential applications in personalized medicine and synthetic biology, with recommendations focusing on investing in R&D and forming strategic collaborations to foster innovation.

However, challenges include ethical concerns regarding gene editing, complex regulatory frameworks, and the potential for off-target effects that could lead to unintentional genetic mutations. Furthermore, intellectual property disputes may limit market dynamics. Addressing these limitations through transparency in data sharing, enhancing CRISPR-Cas systems' fidelity, and developing robust ethical guidelines would be crucial. Promising avenues for innovation include developing next-generation CRISPR systems with improved specificity and safety, applications in biofuels, and novel gene-editing tools for complex traits manipulation. Given the market's evolving nature, a proactive approach in tracking regulatory changes, participating in policy dialogues, and engaging with ethical advisory groups can position companies advantageously. The CRISPR & Cas Genes market is poised for substantial growth, characterized by rapid technological developments and a high potential for cross-sectoral applications, yet it requires navigating numerous regulatory and ethical challenges to realize its full potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving CRISPR & Cas Genes Market

The CRISPR & Cas Genes Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Development of CRISPR-based diagnostic assays for sample tissue screening
  • High prevalence of genetic disorders
  • Rising application in drug discovery, biomedical research, and non-transgenic bleeding
• Market Restraints
  • Off-target effects of CRISPR technology
• Market Opportunities
  • Evolution of anti-CRISPR protein
  • Research and development for novel application of CRISPR-Cas genes
• Market Challenges
  • Patent landscape and dispute

Porter's Five Forces: A Strategic Tool for Navigating the CRISPR & Cas Genes Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the CRISPR & Cas Genes Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the CRISPR & Cas Genes Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the CRISPR & Cas Genes Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the CRISPR & Cas Genes Market

A detailed market share analysis in the CRISPR & Cas Genes Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the CRISPR & Cas Genes Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the CRISPR & Cas Genes Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the CRISPR & Cas Genes Market

A strategic analysis of the CRISPR & Cas Genes Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the CRISPR & Cas Genes Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca plc, Beam Therapeutics Inc., Beckman Coulter, Inc., Calyxt, Inc., Caribou Biosciences, Inc., CRISPR Therapeutics AG, Danaher Corporation, Editas Medicine, Inc., Hera Biolabs, Horizon Discovery Group Plc, Inscripta, Inc., Integrated Dna Technologies, Inc., Intellia Therapeutics, Inc., Lonza Group, and Mammoth Biosciences.

Market Segmentation & Coverage

This research report categorizes the CRISPR & Cas Genes Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Component, market is studied across Product and Service. The Product is further studied across Antibodies, Design Tool, Kits & Enzymes, and Libraries. The Kits & Enzymes is further studied across DNA-Free Cas and Vector-Based Cas. The Service is further studied across Cell Line Engineering, DNA Synthesis, gRNA Design, and Microbial Gene Editing.
• Based on Application, market is studied across Agricultural and Biomedical. The Biomedical is further studied across Disease Model Studies, Epigenetics, Functional Genomics, and Genome Engineering.
• Based on End-user, market is studied across Academics & Government Research Institutes, Biotechnology & Pharmaceutical Companies, and Contract Research Organizations.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Development of CRISPR-based diagnostic assays for sample tissue screening
    • 5.1.1.2. High prevalence of genetic disorders
    • 5.1.1.3. Rising application in drug discovery, biomedical research, and non-transgenic bleeding
  • 5.1.2. Restraints
    • 5.1.2.1. Off-target effects of CRISPR technology
  • 5.1.3. Opportunities
    • 5.1.3.1. Evolution of anti-CRISPR protein
    • 5.1.3.2. Research and development for novel application of CRISPR-Cas genes
  • 5.1.4. Challenges
    • 5.1.4.1. Patent landscape and dispute
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. CRISPR & Cas Genes Market, by Component

• 6.1. Introduction
• 6.2. Product
  • 6.2.1. Antibodies
  • 6.2.2. Design Tool
  • 6.2.3. Kits & Enzymes
    • 6.2.3.1. DNA-Free Cas
    • 6.2.3.2. Vector-Based Cas
  • 6.2.4. Libraries
• 6.3. Service
  • 6.3.1. Cell Line Engineering
  • 6.3.2. DNA Synthesis
  • 6.3.3. gRNA Design
  • 6.3.4. Microbial Gene Editing

7. CRISPR & Cas Genes Market, by Application

• 7.1. Introduction
• 7.2. Agricultural
• 7.3. Biomedical
  • 7.3.1. Disease Model Studies
  • 7.3.2. Epigenetics
  • 7.3.3. Functional Genomics
  • 7.3.4. Genome Engineering

8. CRISPR & Cas Genes Market, by End-user

• 8.1. Introduction
• 8.2. Academics & Government Research Institutes
• 8.3. Biotechnology & Pharmaceutical Companies
• 8.4. Contract Research Organizations

9. Americas CRISPR & Cas Genes Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific CRISPR & Cas Genes Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa CRISPR & Cas Genes Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AstraZeneca plc
• 2. Beam Therapeutics Inc.
• 3. Beckman Coulter, Inc.
• 4. Calyxt, Inc.
• 5. Caribou Biosciences, Inc.
• 6. CRISPR Therapeutics AG
• 7. Danaher Corporation
• 8. Editas Medicine, Inc.
• 9. Hera Biolabs
• 10. Horizon Discovery Group Plc
• 11. Inscripta, Inc.
• 12. Integrated Dna Technologies, Inc.
• 13. Intellia Therapeutics, Inc.
• 14. Lonza Group
• 15. Mammoth Biosciences